Effect of Resveratrol and Pharmacist Intervention on Diabetes Mellitus and Its Neuropathic Complication
Status:
Completed
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
Management of symptoms associated with diabetic neuropathy is a difficult issue for
clinicians since it usually does not respond to standard analgesics. Resveratrol is a
naturally occurring plant-derived, polyphenolic compound, it exerts pleiotropic activity. The
investigators believed that the implementation of multidisciplinary approaches including
pharmacotherapy and provision of healthcare professional services such as pharmacist
intervention are needed for alleviation of diabetic associated neuropathy.Therefore, the
hypothesis of the present protocol is that the administration of resveratrol and/or provision
of pharmaceutical care in patients with diabetic neuropathy might be of value in improving
quality of life and managing diabetic neuropathic pain.The study is designed as a four-arm
randomized, placebo-controlled clinical trial. Group one will be given only conventional
hypoglycemic drugs. Group two patients will receive conventional hypoglycemic drugs
accompanied by pharmacist interventions. Group three; patients will receive resveratrol 500
mg orally once daily after meals for three months, in addition to their regular hypoglycemic
drugs. Group four; patients will receive resveratrol 500 mg orally once daily after meals
along with their regular hypoglycemic drugs for a period of three months, accompanied by
pharmacist interventions. Neuropathic pain will be measured by various neuropathic pain
assessment tools. Nerve conduction studies will be performed to assess the effect of
interventional therapy. The expected outcome will be the improvement of diabetic neuropathy
associated symptoms along with glycemic status.